Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Amortization of Deferred Charges: 2019-2024

Historic Amortization of Deferred Charges for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Dec 2024 value amounting to $1.7 million.

  • Mirum Pharmaceuticals' Amortization of Deferred Charges rose 4.48% to $443,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year increase of 4.56%. This contributed to the annual value of $1.7 million for FY2024, which is 48.70% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Amortization of Deferred Charges of $1.7 million as of FY2024, which was up 48.70% from $1.1 million recorded in FY2023.
  • In the past 5 years, Mirum Pharmaceuticals' Amortization of Deferred Charges registered a high of $1.7 million during FY2024, and its lowest value of $318,000 during FY2020.
  • Its 2-year average for Amortization of Deferred Charges is $1.4 million, with a median of $1.4 million in 2023.
  • Data for Mirum Pharmaceuticals' Amortization of Deferred Charges shows a peak YoY soared of 71.89% (in 2020) over the last 5 years.
  • Mirum Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $318,000 in 2020, then reached $1.1 million in 2023, then spiked by 48.70% to $1.7 million in 2024.